Zydus gets zero USFDA observations for Ahmedabad animal health drug manufacturing facility
Advertisement
Ahmedabad: Through a recent BSE filing, Zydus Lifesciences Ltd. has informed that the US Food and Drug Administration (USFDA) has concluded the inspection with nil observations at the group’s animal health drug manufacturing facility at SEZ, Ahmedabad.
The inspection was conducted from 30th May to 2nd June, 2023.
Medical Dialogues team had earlier reported that the USFDA had concluded an inspection with three observations at Zydus Lifesciences's manufacturing facility SEZ-1 located at Pharmez, Ahmedabad.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.